335 related articles for article (PubMed ID: 28637878)
1. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
2. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
3. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
4. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
6. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
7. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
8. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
[TBL] [Abstract][Full Text] [Related]
9. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
[TBL] [Abstract][Full Text] [Related]
10. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
[TBL] [Abstract][Full Text] [Related]
11. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses.
Heer AK; Shamshiev A; Donda A; Uematsu S; Akira S; Kopf M; Marsland BJ
J Immunol; 2007 Feb; 178(4):2182-91. PubMed ID: 17277123
[TBL] [Abstract][Full Text] [Related]
12. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
13. Effect of TLR3 and TLR7 activation in uterine NK cells from non-obese diabetic (NOD) mice.
Lin Y; Ren L; Wang W; Di J; Zeng S; Saito S
J Reprod Immunol; 2009 Oct; 82(1):12-23. PubMed ID: 19560213
[TBL] [Abstract][Full Text] [Related]
14. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.
Przewoznik M; Hömberg N; Naujoks M; Pötzl J; Münchmeier N; Brenner CD; Anz D; Bourquin C; Nelson PJ; Röcken M; Mocikat R
J Immunother; 2012 Apr; 35(3):217-22. PubMed ID: 22421939
[TBL] [Abstract][Full Text] [Related]
15. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
19. CD4
Kruse B; Buzzai AC; Shridhar N; Braun AD; Gellert S; Knauth K; Pozniak J; Peters J; Dittmann P; Mengoni M; van der Sluis TC; Höhn S; Antoranz A; Krone A; Fu Y; Yu D; Essand M; Geffers R; Mougiakakos D; Kahlfuß S; Kashkar H; Gaffal E; Bosisio FM; Bechter O; Rambow F; Marine JC; Kastenmüller W; Müller AJ; Tüting T
Nature; 2023 Jun; 618(7967):1033-1040. PubMed ID: 37316667
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment.
Pilch Z; Tonecka K; Braniewska A; Sas Z; Skorzynski M; Boon L; Golab J; Meyaard L; Rygiel TP
Cancer Immunol Res; 2018 Aug; 6(8):930-940. PubMed ID: 30021725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]